Alnylam Pharmaceuticals

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the originator of RNA interference (RNAi) therapeutics—a groundbreaking method for treating diseases by “silencing” the genes responsible for causing or contributing to them. Established in 2002 by a team of distinguished researchers and biotech pioneers, Alnylam’s efforts over more than twenty years have produced the essential discoveries and progress that have enabled the field of RNAi therapeutics. In 2018, our first commercial product, and the first RNAi therapeutic worldwide, received approval. Since then, four additional Alnylam-developed medicines have gained approval, and we are actively working on new treatments for both rare and common conditions. We are a global, varied team of more than 2,500 individuals. We take pride in cultivating a fun, welcoming, and energetic workplace where employees can reach their greatest potential. As a result, we are frequently recognized as a top employer by The Boston Globe (2015-24), Science Magazine (2018-24), Fast Company (Best Workplaces for Innovators 2020-25), and LinkedIn (2024). Our headquarters is in Cambridge, Massachusetts (U.S.), with additional offices across North America, Europe, Asia, and South America. Check our social media community guidelines: https://bit.ly/2FcRhJy. Important: To report an adverse event or a product complaint, email medinfo@alnylam.com or contact us by phone at the following numbers: for North America, 877.ALNYLAM (877.256.9526); for Europe, +31 20 369 7861.